logo

SUPN

SupernusยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

SUPN Profile

Supernus Pharmaceuticals, Inc.

A biopharmaceutical company that focused products for the treatment of central nervous system diseases

Pharmaceutical
03/30/2005
05/01/2012
NASDAQ Stock Exchange
674
12-31
Common stock
9715 Key West Avenue , Rockville , MD 20850
--
Supernus Pharmaceuticals, Inc., was incorporated in Delaware on March 30, 2005 and commenced operations on December 22, 2005. The Company is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system diseases. The company's diverse neuroscience portfolio includes approved treatments for attention deficit hyperactivity disorder, dyskinesia in Parkinson's disease patients treated with levodopa, low activity in PD, epilepsy, migraine, cervical dystonia and chronic saliva flow. The company is developing a broad range of novel CNS product candidates, including new potential therapies for the treatment of epilepsy, depression and other CNS disorders.